<p><strong>新加坡，2025 年 12 月 30 日（GLOBE NEWSWIRE）--</strong> EUDA Health Holdings Limited（納斯達克：EUDA）“EUDA” 或 “公司”，是一家總部位於新加坡的非侵入性醫療保健提供商，專注於新加坡、馬來西亞和中國，今天宣佈在中國推出其全國性的幹細胞提取、低温存儲和臨牀交付平台。公司已與深圳英諾免疫有限公司和武漢凱恩醫院建立合作關係，繼續擴展其全國臨牀和物流網絡。該平台標誌着 EUDA 在幹細胞戰略持續推進中的重要一步，進一步擴展了其在細胞提取、處理、低温存儲、物流和臨牀應用方面的能力。</p>
<p><strong>核心平台設計原則</strong></p>
<p>EUDA 的平台圍繞三個核心原則設計：集中處理與分散訪問相結合，以確保質量和合規性而不限制地理覆蓋範圍；長期細胞保存，使患者能夠在生命早期存儲生物材料以備未來臨牀使用；與長壽醫學的整合，使細胞服務嵌入更廣泛的預防、再生和個性化健康計劃中。</p>
<p><strong>國家幹細胞提取和低温存儲基礎設施</strong></p>
<p>EUDA 的平台被設計為一個閉環、合規的操作系統，使患者能夠在廣泛的地理範圍內訪問幹細胞服務，同時保持集中處理標準。</p>
<p>關鍵要素包括：</p>
<p>• 深圳英諾免疫有限公司作為 EUDA 在中國南方的主要細胞處理和低温存儲中心，初步設計的低温存儲能力約為 50,000 個患者細胞單位，處於受控條件下。</p>
<p>• 武漢凱恩醫院作為 EUDA 在中國中部的臨牀和長壽旗艦，計劃的低温生物存儲和臨牀能力設計支持約 200,000 個患者細胞單位，整合住院、門診和長期健康管理服務。</p>
<p>• 通過合作診所網絡提供全國臨牀接入層，支持本地提取和下游臨牀交付。</p>
<p><strong>武漢凱恩醫院</strong></p>
<p>武漢凱恩醫院是一家以長壽為重點的優質健康管理醫院，定位為五星級綜合抗衰老和預防醫療中心，彙集再生醫學、非藥物慢性病管理、激素和代謝平衡、免疫支持、早期預警診斷和個性化長期健康規劃於一體。它被建立為整合先進診斷和早期疾病風險檢測、再生和基於細胞的醫療技術、個性化健康管理程序以及跨學科臨牀團隊的旗艦模型，涵蓋再生醫學、內分泌學、心血管健康、免疫健康和長壽科學。在 EUDA 的平台下，武漢凱恩醫院將同時作為臨牀交付地點和中部地區幹細胞處理、存儲和臨牀轉化的中心節點。</p>
<p><strong>分佈式臨牀接入和集中處理網絡</strong></p>
<p>為了實現全國範圍的接入，EUDA 正在與兩家戰略基礎設施合作伙伴合作。廣東萬海細胞生物技術有限公司運營着一個全國性的網絡，包括符合 cGMP 標準的實驗室、區域細胞製備中心和附屬臨牀製備及治療場所，以及覆蓋中國 20 多個省市的約 200 個製備和治療診所的廣泛網絡，提供合格患者進行提取、臨牀製備和後處理協調的物理接入點。順豐冷鏈物流有限公司專注於受監管的、温控的城際運輸細胞和生物材料，支持在受控冷鏈條件下在提取診所、處理設施和治療中心之間安全運輸患者樣本。</p>
<p>通過這一綜合結構，患者可以在全國合作伙伴網絡內的參與診所進行幹細胞提取，提取的細胞材料隨後在冷鏈協議下運輸到深圳英諾免疫或武漢凱恩醫院進行處理和低温存儲。當臨牀適宜時，準備好的細胞產品會被運輸回指定診所供患者使用，物流協調和監護鏈追蹤通過專用的生物醫學冷鏈系統進行管理。這一架構使 EUDA 能夠提供地理分佈的接入，同時保持集中質量控制，支持可擴展性，同時保持處理一致性。</p>
<p><strong>EUDA 首席執行官阿爾弗雷德·林（Mr Alfred Lim）評論道：</strong></p>
<p>“這個平台改變了再生醫學在中國的獲取和交付方式。我們不是在孤立的診所或實驗室，而是在構建一個協調的國家系統，將提取、低温存儲、物流和臨牀交付連接成一個綜合生態系統。以深圳英諾免疫和武漢凱恩醫院為我們的支柱，結合我們的全國診所和物流合作伙伴的擴展，我們相信我們正在為該地區創造一個全面且可擴展的再生醫學接入基礎設施。”</p>
<p><strong>關於 EUDA Health Holdings Limited</strong></p>
<p>EUDA Health Holdings Limited（納斯達克代碼：EUDA）是一家總部位於新加坡的領先非侵入性醫療服務提供商，專注於新加坡、馬來西亞和中國。該公司旨在成為非侵入性和預防性醫療領域的市場領導者，戰略重點放在快速增長的長壽產業上。我們的使命是滿足該地區超過 18 億人不斷變化的醫療需求，該地區正經歷顯著的人口結構變化，超過 30% 的人口迅速老齡化。通過提供創新、可及且有科學依據的健康解決方案，EUDA 致力於引領區域醫療從被動的醫療治療轉向主動的、以長壽為中心的護理。EUDA 還經營一家總部位於新加坡的物業管理業務。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本文件可能包含關於風險和不確定性的前瞻性聲明。這些聲明通常使用前瞻性詞彙，例如 “估計”、“預測”、“期望”、“設想”、“預期”、“預測”、“計劃”、“打算”、“相信”、“尋求”、“可能”、“將”、“應該”、“未來”、“提議” 及這些詞的變體或類似表達（或這些詞或表達的否定版本）。這些前瞻性聲明並不保證未來的表現、條件或結果，並涉及許多已知和未知的風險、不確定性、假設和其他重要因素，其中許多超出了 EUDA 的控制範圍，可能導致實際結果或結果與前瞻性聲明中討論的內容有重大差異。您不應過度依賴僅適用於本文件發佈之日的前瞻性聲明。除法律要求外，公司不承擔更新或修訂任何前瞻性聲明的義務，無論是由於新信息、未來事件還是其他原因。</p>
<p><strong>聯繫方式</strong></p>
<p>Christensen Advisory</p>
<p>Linda Bergkamp</p>
<p>電話：+1-480-614-3004</p>
<p>電子郵件：linda.bergkamp@christensencomms.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9ERTNNaU0zTXpNNU5qUTFJelV3TURFeU5EUXpPUT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9ERTNNaU0zTXpNNU5qUTFJelV3TURFeU5EUXpPUT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OGI2MTUxM2ItNTk1MC00MDFjLTk0NDAtYjZlMzMxYzVjYzhiLTUwMDEyNDQzOS0yMDI1LTEyLTMwLWVu/tiny/EUDA-Health-Holdings-Ltd.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OGI2MTUxM2ItNTk1MC00MDFjLTk0NDAtYjZlMzMxYzVjYzhiLTUwMDEyNDQzOS0yMDI1LTEyLTMwLWVu/tiny/EUDA-Health-Holdings-Ltd.png"/></p>

EUDA

<p>EUDA Health Holdings Limited 在中國推出了一項全國性的幹細胞提取、冷凍儲存和臨牀交付平台，合作伙伴包括深圳創新免疫和武漢凱恩醫院。該平台旨在通過集中處理系統和分散訪問來增強再生醫學的可及性。主要特點包括在中國南方具備 50,000 個患者細胞單位的低温儲存能力，在中國中部則為 200,000 個，並由提取和治療的診所網絡支持。首席執行官阿爾弗雷德·林強調了在該地區建立全面再生醫學基礎設施的重要性</p>

<p><strong>SINGAPORE, Dec. 30, 2025 (GLOBE NEWSWIRE) --</strong> EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company,” a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced the launch of its nationwide stem cell extraction, cryogenic storage and clinical delivery platform in China. The Company has partnered with Shenzhen Inno Immune Co., Ltd. and Wuhan Kaien Hospital as the Company continues to expand its national clinical and logistics network. This platform marks a major step in EUDA’s continued advancement of its stem cell strategy, further extending its capabilities across cell extraction, processing, cryogenic storage, logistics and clinical application.</p>
<div class="lb-trans"><p><strong>新加坡，2025 年 12 月 30 日（GLOBE NEWSWIRE）--</strong> EUDA Health Holdings Limited（納斯達克：EUDA）“EUDA” 或 “公司”，是一家總部位於新加坡的非侵入性醫療保健提供商，專注於新加坡、馬來西亞和中國，今天宣佈在中國推出其全國性的幹細胞提取、低温存儲和臨牀交付平台。公司已與深圳英諾免疫有限公司和武漢凱恩醫院建立合作關係，繼續擴展其全國臨牀和物流網絡。該平台標誌着 EUDA 在幹細胞戰略持續推進中的重要一步，進一步擴展了其在細胞提取、處理、低温存儲、物流和臨牀應用方面的能力。</p>
</div><p><strong>Core Platform Design Principles</strong></p>
<div class="lb-trans"><p><strong>核心平台設計原則</strong></p>
</div><p>EUDA’s platform is designed around three core principles: centralized processing with decentralized access to ensure quality and compliance without limiting geographic reach, long-term cell preservation to enable patients to store biological material earlier in life for potential future clinical use, and integration with longevity medicine so that cell services are embedded within broader preventive, regenerative and personalized health programs.</p>
<div class="lb-trans"><p>EUDA 的平台圍繞三個核心原則設計：集中處理與分散訪問相結合，以確保質量和合規性而不限制地理覆蓋範圍；長期細胞保存，使患者能夠在生命早期存儲生物材料以備未來臨牀使用；與長壽醫學的整合，使細胞服務嵌入更廣泛的預防、再生和個性化健康計劃中。</p>
</div><p><strong>National Stem Cell Extraction and Cryostorage Infrastructure</strong></p>
<div class="lb-trans"><p><strong>國家幹細胞提取和低温存儲基礎設施</strong></p>
</div><p>EUDA’s platform is designed as a closed-loop, compliant operating system that enables patients to access stem cell services across a wide geographic footprint while maintaining centralized processing standards.</p>
<div class="lb-trans"><p>EUDA 的平台被設計為一個閉環、合規的操作系統，使患者能夠在廣泛的地理範圍內訪問幹細胞服務，同時保持集中處理標準。</p>
</div><p>Key elements include:</p>
<div class="lb-trans"><p>關鍵要素包括：</p>
</div><p>• Shenzhen Inno Immune Co., Ltd. as EUDA’s primary cell processing and cryogenic storage hub in Southern China, with an initial designed cryogenic storage capacity of approximately 50,000 patient cell units under controlled conditions.</p>
<div class="lb-trans"><p>• 深圳英諾免疫有限公司作為 EUDA 在中國南方的主要細胞處理和低温存儲中心，初步設計的低温存儲能力約為 50,000 個患者細胞單位，處於受控條件下。</p>
</div><p>• Wuhan Kaien Hospital as EUDA’s Central China clinical and longevity flagship, with a planned cryogenic biostorage and clinical capacity designed to support up to approximately 200,000 patient cell units, integrated with inpatient, outpatient and long-term health management services.</p>
<div class="lb-trans"><p>• 武漢凱恩醫院作為 EUDA 在中國中部的臨牀和長壽旗艦，計劃的低温生物存儲和臨牀能力設計支持約 200,000 個患者細胞單位，整合住院、門診和長期健康管理服務。</p>
</div><p>• A nationwide clinical access layer via partner clinic networks enabling local extraction and downstream clinical delivery.</p>
<div class="lb-trans"><p>• 通過合作診所網絡提供全國臨牀接入層，支持本地提取和下游臨牀交付。</p>
</div><p><strong>Wuhan Kaien Hospital</strong></p>
<div class="lb-trans"><p><strong>武漢凱恩醫院</strong></p>
</div><p>Wuhan Kaien Hospital is a premium longevity-focused health management hospital positioned as a five-star, integrated anti-aging and preventive healthcare center that brings together regenerative medicine, non-drug chronic disease management, hormone and metabolic balance, immune support, early-warning diagnostics and personalized long-term health planning within one institutional setting. It was established as a flagship model for integrating advanced diagnostics and early disease risk detection, regenerative and cell-based medical technologies, personalized health management programs and multidisciplinary clinical teams spanning regenerative medicine, endocrinology, cardiovascular health, immune health and longevity science. Under EUDA’s platform, Wuhan Kaien Hospital will serve both as a clinical delivery site and as a central node for stem cell processing, storage and clinical translation in Central China.</p>
<div class="lb-trans"><p>武漢凱恩醫院是一家以長壽為重點的優質健康管理醫院，定位為五星級綜合抗衰老和預防醫療中心，彙集再生醫學、非藥物慢性病管理、激素和代謝平衡、免疫支持、早期預警診斷和個性化長期健康規劃於一體。它被建立為整合先進診斷和早期疾病風險檢測、再生和基於細胞的醫療技術、個性化健康管理程序以及跨學科臨牀團隊的旗艦模型，涵蓋再生醫學、內分泌學、心血管健康、免疫健康和長壽科學。在 EUDA 的平台下，武漢凱恩醫院將同時作為臨牀交付地點和中部地區幹細胞處理、存儲和臨牀轉化的中心節點。</p>
</div><p><strong>Distributed Clinical Access and Centralized Processing Network</strong></p>
<div class="lb-trans"><p><strong>分佈式臨牀接入和集中處理網絡</strong></p>
</div><p>To enable nationwide access, EUDA is working with two strategic infrastructure partners. Guangdong Wanhai Cell Biotechnology Co., Ltd. operates a nationwide footprint comprising cGMP-standardized laboratories, regional cell preparation centers and affiliated clinical preparation and treatment sites, and an extensive network of approximately 200 preparation and treatment clinics across more than 20 provinces and cities in China, providing physical access points where eligible patients can undergo extraction, clinical preparation and post-processing coordination. Shunfeng Cold Chain Logistics Co., Ltd. specializes in regulated, temperature-controlled intercity transport of cellular and biological materials and supports the secure movement of patient samples between extraction clinics, processing facilities and treatment centers under controlled cold-chain conditions.</p>
<div class="lb-trans"><p>為了實現全國範圍的接入，EUDA 正在與兩家戰略基礎設施合作伙伴合作。廣東萬海細胞生物技術有限公司運營着一個全國性的網絡，包括符合 cGMP 標準的實驗室、區域細胞製備中心和附屬臨牀製備及治療場所，以及覆蓋中國 20 多個省市的約 200 個製備和治療診所的廣泛網絡，提供合格患者進行提取、臨牀製備和後處理協調的物理接入點。順豐冷鏈物流有限公司專注於受監管的、温控的城際運輸細胞和生物材料，支持在受控冷鏈條件下在提取診所、處理設施和治療中心之間安全運輸患者樣本。</p>
</div><p>Through this integrated structure, patients may undergo stem cell extraction at participating clinics within the national partner network, after which extracted cellular material is transported under cold-chain protocols to Shenzhen Inno Immune or Wuhan Kaien Hospital for processing and cryogenic storage. When clinically appropriate, prepared cell products are transported back to designated clinics for patient administration, with logistics coordination and chain-of-custody tracking managed through dedicated biomedical cold-chain systems. This architecture allows EUDA to offer geographically distributed access with centralized quality control, supporting scalability while maintaining processing consistency.</p>
<div class="lb-trans"><p>通過這一綜合結構，患者可以在全國合作伙伴網絡內的參與診所進行幹細胞提取，提取的細胞材料隨後在冷鏈協議下運輸到深圳英諾免疫或武漢凱恩醫院進行處理和低温存儲。當臨牀適宜時，準備好的細胞產品會被運輸回指定診所供患者使用，物流協調和監護鏈追蹤通過專用的生物醫學冷鏈系統進行管理。這一架構使 EUDA 能夠提供地理分佈的接入，同時保持集中質量控制，支持可擴展性，同時保持處理一致性。</p>
</div><p><strong>Mr Alfred Lim, CEO of EUDA, commented:</strong></p>
<div class="lb-trans"><p><strong>EUDA 首席執行官阿爾弗雷德·林（Mr Alfred Lim）評論道：</strong></p>
</div><p>“This platform transforms how regenerative medicine is accessed and delivered in China. Instead of isolated clinics or laboratories, we are building a coordinated national system connecting extraction, cryogenic storage, logistics and clinical delivery into one integrated ecosystem. With Shenzhen Inno Immune and Wuhan Kaien Hospital as our anchors, and our national clinic and logistics partners extending reach, we believe we are creating a comprehensive and scalable infrastructure for regenerative medicine access in the region.”</p>
<div class="lb-trans"><p>“這個平台改變了再生醫學在中國的獲取和交付方式。我們不是在孤立的診所或實驗室，而是在構建一個協調的國家系統，將提取、低温存儲、物流和臨牀交付連接成一個綜合生態系統。以深圳英諾免疫和武漢凱恩醫院為我們的支柱，結合我們的全國診所和物流合作伙伴的擴展，我們相信我們正在為該地區創造一個全面且可擴展的再生醫學接入基礎設施。”</p>
</div><p><strong>About EUDA Health Holdings Limited</strong></p>
<div class="lb-trans"><p><strong>關於 EUDA Health Holdings Limited</strong></p>
</div><p>EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.</p>
<div class="lb-trans"><p>EUDA Health Holdings Limited（納斯達克代碼：EUDA）是一家總部位於新加坡的領先非侵入性醫療服務提供商，專注於新加坡、馬來西亞和中國。該公司旨在成為非侵入性和預防性醫療領域的市場領導者，戰略重點放在快速增長的長壽產業上。我們的使命是滿足該地區超過 18 億人不斷變化的醫療需求，該地區正經歷顯著的人口結構變化，超過 30% 的人口迅速老齡化。通過提供創新、可及且有科學依據的健康解決方案，EUDA 致力於引領區域醫療從被動的醫療治療轉向主動的、以長壽為中心的護理。EUDA 還經營一家總部位於新加坡的物業管理業務。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p>
<div class="lb-trans"><p>本文件可能包含關於風險和不確定性的前瞻性聲明。這些聲明通常使用前瞻性詞彙，例如 “估計”、“預測”、“期望”、“設想”、“預期”、“預測”、“計劃”、“打算”、“相信”、“尋求”、“可能”、“將”、“應該”、“未來”、“提議” 及這些詞的變體或類似表達（或這些詞或表達的否定版本）。這些前瞻性聲明並不保證未來的表現、條件或結果，並涉及許多已知和未知的風險、不確定性、假設和其他重要因素，其中許多超出了 EUDA 的控制範圍，可能導致實際結果或結果與前瞻性聲明中討論的內容有重大差異。您不應過度依賴僅適用於本文件發佈之日的前瞻性聲明。除法律要求外，公司不承擔更新或修訂任何前瞻性聲明的義務，無論是由於新信息、未來事件還是其他原因。</p>
</div><p><strong>Contact</strong></p>
<div class="lb-trans"><p><strong>聯繫方式</strong></p>
</div><p>Christensen Advisory</p>
<div class="lb-trans"><p>Christensen Advisory</p>
</div><p>Linda Bergkamp</p>
<div class="lb-trans"><p>Linda Bergkamp</p>
</div><p>Phone: +1-480-614-3004</p>
<div class="lb-trans"><p>電話：+1-480-614-3004</p>
</div><p>E-mail: linda.bergkamp@christensencomms.com</p>
<div class="lb-trans"><p>電子郵件：linda.bergkamp@christensencomms.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE9ERTNNaU0zTXpNNU5qUTFJelV3TURFeU5EUXpPUT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxODE3MiM3MzM5NjQ1IzUwMDEyNDQzOQ=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/OGI2MTUxM2ItNTk1MC00MDFjLTk0NDAtYjZlMzMxYzVjYzhiLTUwMDEyNDQzOS0yMDI1LTEyLTMwLWVu/tiny/EUDA-Health-Holdings-Ltd.png" alt="" original-src="https://ml.globenewswire.com/media/OGI2MTUxM2ItNTk1MC00MDFjLTk0NDAtYjZlMzMxYzVjYzhiLTUwMDEyNDQzOS0yMDI1LTEyLTMwLWVu/tiny/EUDA-Health-Holdings-Ltd.png"/></p>

EUDA Launches Nationwide Stem Cell Extraction, Cryostorage and Clinical Delivery Platform in China with Shenzhen Inno Immune and Wuhan Kaien Hospital | EUDA Stock News

Euda Health 在中國與深圳 Inno Immune 和武漢凱恩醫院合作推出全國性的幹細胞提取、冷凍儲存和臨牀交付平台 | Euda Health 股票新聞